Regulation of CYP3A4 and CYP3A5 expression and modulation of " intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor

Molecular and Cellular Endocrinology

Volumn 364, Issue 1-2, 2012, Pages 54-64

  Maguire, Orla ^a,c   Pollock, Catherine ^c   Martin, Philip ^b   Owen, Andrew ^b   Smyth, Thomas ^a   Doherty, Declan ^a   Campbell, Moray J ^c   McClean, Stephen ^a   Thompson, Paul ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CYP3A4; CYP3A5; Metabolism; Prostate; Vitamin D receptor

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; VITAMIN D RECEPTOR;

ANDROGEN METABOLISM; ARTICLE; BINDING AFFINITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TESTOSTERONE METABOLISM; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

EID: 84867569007     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.08.007     Document Type: Article

References (47)

1. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends. Endocrinol. Metab. 2004, 15:432-438.
2. Bertilsson G., Berkenstam A., Blomquist P. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 2001, 280:139-144.
3. Burk O., Koch I., Raucy J., Hustert E., Eichelbaum M., Brockmöller J., Zanger U.M., Wojnowski L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem. 2004, 279:38379-38385.
4. Cleutjens K.B., van der Korput H.A., Ehren-van Eekelen C.C., Sikes R.A., Fasciana C., Chung L.W., Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol. Endocrinol. 1997, 11:1256-1265.
5. Finnström N., Bjelfman C., Söderström T.G., Smith G., Egevad L., Norlén B.J., Wolf C.R., Rane A. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 2001, 31:880-886.
6. Fujimura T., Takahashi S., Urano T., Kumagai J., Murata T., Takayama K., Ogushi T., Horie-Inoue K., Ouchi Y., Kitamura T., Muramatsu M., Homma Y., Inoue S. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009, 74:391-397.
7. Goldenberg S.L., Gleave M.E., Taylor D., Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years follow-up. Mol. Urol. 1999, 3:287-292.
8. Grigoryev D.N., Long B.J., Njar V.C., Brodie A.H. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid. Biochem. Mol. Biol. 2000, 75:1-10.
9. Hara H., Yasunami Y., Adachi T. Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene. Biochem. Biophys. Res. Commun. 2004, 321:909-915.
10. Holt S.K., Kwon E.M., Koopmeiners J.S., Lin D.W., Feng Z., Ostrander E.A., Peters U., Stanford J.L. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010, 70:1448-1460.
11. Huang S.P., Huang C.Y., Wu W.J., Pu Y.S., Chen J., Chen Y.Y., Yu C.C., Wu T.T., Wang J.S., Lee Y.H., Huang J.K., Huang C.H., Wu M.T. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int. J. Cancer 2006, 119:1902-1907.
12. Hull M.W., Montaner J.S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 2011, 43:375-388.
13. Ikezoe T., Hisatake Y., Takeuchi T., Ohtsuki Y., Yang Y., Said J.W., Taguchi H., Koeffler H.P. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004, 64:7426-7431.
14. Kumar G.N., Dykstra J.Y., Roberts E.M., Jayanti V.K., Hickman D., Uchic J., Yao Y., Surber B., Thomas S., Granneman G.R. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug. Metab. Dispos. 1999, 27:902-908.
15. Leskelä S., Honrado E., Montero-Conde C., Landa I., Cascón A., Letón R., Talavera P., Cózar J.M., Concha A., Robledo M., Rodríguez-Antona C. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr. Relat. Cancer 2007, 14:645-654.
16. Li A.P., Kaminski D.L., Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995, 104:1-8.
17. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., Ettinger S.L., Gleave M.E., Nelson C.C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008, 68:6407-6415.
18. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., Haussler M.R., Mangelsdorf D.J. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
19. Matsubara T., Yoshinari K., Aoyama K., Sugawara M., Sekiya Y., Nagata K., Yamazoe Y. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug. Metab. Dispos. 2008, 36. 2058-6.
20. Mizokami A., Koh E., Fujita H., Maeda Y., Egawa M., Koshida K., Honma S., Keller E.T., Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004, 64:765-771.
21. Moilanen A.M., Hakkola J., Vaarala M.H., Kauppila S., Hirvikoski P., Vuoristo J.T., Edwards R.J., Paavonen T.K. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 2007, 28:916-921.
22. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
23. Mostaghel E.A., Nelson P.S. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best. Pract. Res. Clin. Endocrinol. Metab. 2008, 22:243-258.
24. Oldfield V., Plosker G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006, 66:1275-1299.
25. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., Casey G., Witte J.S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers. Prev. 1999, 8:901-905.
26. Parkinson A., Mudra D.R., Johnson C., Dwyer A., Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 199:193-209.
27. Pascussi J.M., Gerbal-Chaloin S., Drocourt L., Maurel P., Vilarem M.J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003, 1619:243-253.
28. Pavek P., Pospechova K., Svecova L., Syrova Z., Stejskalova L., Blazkova J., Dvorak Z., Blahos J. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem. Pharmacol. 2010, 79:277-287.
29. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 2004, 18:1109-1119.
30. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1665-1671.
31. Plummer S.J., Conti D.V., Paris P.L., Curran A.P., Casey G., Witte J.S. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12:928-932.
32. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 1998, 90:1225-1229.
33. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res. 1990, 10:1307-1311.
34. Siemes C., Visser L.E., de Jong F.H., Coebergh J.W., Uitterlinden A.G., Hofman A., Stricker B.H., van Schaik R.H. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer-The Rotterdam Study. Steroids 2010, 75:1024-1032.
35. Sinkkonen L., Malinen M., Saavalainen K., Väisänen S., Carlberg C. Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. Nucleic Acids Res. 2005, 33:2440-2451.
36. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
37. Tayeb M.T., Clark C., Haites N.E., Sharp L., Murray G.I., McLeod H.L. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 2003, 88:928-932.
38. Thompson P.D., Jurutka P.W., Whitfield G.K., Myskowski S.M., Eichhorst K.R., Dominguez C.E., Haussler C.A., Haussler M.R. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 2002, 299:730-738.
39. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., Ishizuka H., Kharasch E., Schuetz J., Schuetz E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol. 2001, 60:1399-1406.
40. Vaarala M.H., Mattila H., Ohtonen P., Tammela T.L., Paavonen T.K., Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int. J. Cancer 2008, 122:2511-2516.
41. Waxman D.J., Attisano C., Guengerich F.P., Lapenson D.P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 1988, 263:424-436.
42. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 1991, 290:160-166.
43. Williams H., Powell I.J., Land S.J., Sakr W.A., Hughes M.R., Patel N.P., Heilbrun L.K., Everson R.B. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate 2004, 61:267-275.
44. Wu G., Fan R.S., Li W., Ko T.C., Brattain M.G. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:1555-1563.
45. Xu Y., Shibata A., McNeal J.E., Stamey T.A., Feldman D., Peehl D.M. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol. Biomarkers Prev. 2003, 12:23-27.
46. Yamazaki H., Nakano M., Imai Y., Ueng Y.F., Guengerich F.P., Shimada T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 1996, 325:174-182.
47. Zhang B., Cheng Q., Ou Z., Lee J.H., Xu M., Kochhar U., Ren S., Huang M., Pflug B.R., Xie W. Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 2010, 151:5721-5729.